Bioserve Biotechnologies India Pvt. Ltd. launches NIPT clinical services in India
11 March 2021
Hyderabad India – 11 March 2021: Bioserve Biotechnologies Pvt Ltd, 100% owned subsidiary of REPROCELL Inc, is pleased to announce the launch of Non-Invasive Prenatal Testing (NIPT) services in India.Under PRENITA brand, along with NIPT service launch, Bioserve provides the advanced Preimplantation Genetic Screening / Diagnosis (PGS/PGD), diagnostic testing for prenatal and postnatal cases and carrier screening services. PRENITA tests provide accurate results with actionable insight to the clinician to provide the perfect outcome to the mother and child.
Rama Modali, CEO of Bioserve Biotechnologies Pvt Ltd mentioned: “Bioserve is proud to empower clinician and other experts and provide tools for better services in the area of reproductive health. Bioserve’s expertise in molecular genetics combined with REPROCELL’s global brand power is an exciting combination”
Bioserve Biotechnologies India Pvt. Ltd. has been REPROCELL’s subsidiary since April 2018. Since its inception in 2002, the company has been the prime resource for primer synthesis, DNA sequencing related services, utilizing the Sanger platforms, next generation sequencing services and bioinformatics services for many of the top life science industries, research organizations and academic research institutions across India covering more than 6000 customers.